Uticaj tretmana litijum karbonatom na ishod terapije radioaktivnim jodom kod grejsovog hipertiroidizma

Crucial influence on the outcome of radioiodine therapy (RIT) in Graves’ hyperthyroidism (GH) has the effective half-life of 131I in the gland. The short-term treatment with Lithium carbonate (LiCO3) enhances the 131I half-life and increase the thyroid radiation dose. The aim of this study was to assess the efficacy of RIT combined with LiCO3 in patients with GH. This prospective study included 30 patients treated with 131I-NaI in combination with LiCO3 (RI-Li group), and 30 patients treated only with 131I-NaI (RI group). Treatment with LiCO3 (daily dose of 900 mg) was started one day before RIT and continued six days after. Results: In RI-Li group the serum level of Li was 0.571±0.156 μmol/l at RIT. Despite of significantly increased serum TT4 and FT4 levels, and decreased TSH level in RI group, there were no considerable changes in hormone levels in RI-Li group 7 days after treatment. The successful therapy outcome (euthyroidism or hypothyroidism) was registered in 73.3% of patients from RI and in 90.0% of patients from RI-Li group (p